The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40 KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis
✦ LIBER ✦
Safety and efficacy of combination therapy with peginterferon alfa-2a (40kD) and ribavirin in the outpatient setting: prospective analysis of 197 patients with chronic hepatitis C viral infection
✍ Scribed by Thierry Fontanges; Sylvain Beorchia; Catherine Douvin; Patrick Delassalle; Jean-Marc Combis; Bertrand Hanslik; Jean-Paul Jacques; Bernard Filoche; Hervé Desmorat; Catherine Chandelier; Denis Ouzan
- Book ID
- 114251585
- Publisher
- Masson Editeur
- Year
- 2007
- Tongue
- French
- Weight
- 996 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0399-8320
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Efficacy and safety of peginterferon alf
✍
Savino Bruno; Mitchell L. Shiffman; Stuart K. Roberts; Edward J. Gane; Diethelm
📂
Article
📅
2009
🏛
John Wiley and Sons
🌐
English
⚖ 500 KB
👁 1 views
782 CHRONIC HEPATITIS C GENOTYPE 4: EFFI
✍
M. Diago; J. Boadas; R. Planas; R. Sola; J.A. del Olmo; J. Crespo; J.C. Erdozaín
📂
Article
📅
2008
🏛
Elsevier Science
🌐
English
⚖ 60 KB
454 PREDICTIVE FACTORS OF THROMBOCYTOPEN
✍
S. Mauss; A. Schober; T. Lutz; G. Moog; M. Schuchmann; R. Heyne; C. John; W. Sch
📂
Article
📅
2011
🏛
Elsevier Science
🌐
English
⚖ 152 KB
842 EFFICACY AND TOLERABILITY OF PEGINTE
✍
E. Zehnter; S. Mauss; S. Kaiser; K. Boeker; T. Lutz; R. Heyne; C. John; G. Moog;
📂
Article
📅
2008
🏛
Elsevier Science
🌐
English
⚖ 56 KB
Efficacy and safety of peginterferon alp
✍
Richard Njouom; Michèle Tagni Sartre; Isabelle Timba; Eric Nerrienet; Patrice Tc
📂
Article
📅
2008
🏛
John Wiley and Sons
🌐
English
⚖ 100 KB
👁 1 views
## Abstract Data were examined from a day‐to‐day clinical practice in Yaounde, Cameroon to evaluate the efficacy and safety of peginterferon alfa‐2a and ribavirin in treatment‐naive Cameroonian patients with chronic hepatitis C. Ninety adults with chronic hepatitis C (mean age, 53 ± 8 years; 79% ma
85 ANTIVIRAL ACTIVITY AND SAFETY OF ITMN
✍
N. Forestier; D. Larrey; P. Marcellin; Y. Benhamou; D. Guyader; W. Bradford; S.
📂
Article
📅
2009
🏛
Elsevier Science
🌐
English
⚖ 51 KB